Cochrane2023Ia
Cochrane Review: Interventions for chronic kidney disease in people with sickle cell disease
Zusammenfassung
# Interventions for chronic kidney disease in people with sickle cell disease.
## BACKGROUND
Sickle cell disease (SCD), one of the commonest severe monogenic disorders, is caused by the inheritance of two abnormal haemoglobin (beta-globin) genes. SCD can cause severe pain, significant end-organ damage, pulmonary complications, and premature death. Kidney disease is a frequent and potentially severe complication in people with SCD. Chronic kidney disease (CKD) is defined as abnormalities of kid
Kerninformationen
ickle cell nephropathy, outcomes are poor as a result of the progression to proteinuria and chronic kidney insufficiency. Up to 12% of people who develop sickle cell nephropathy will develop end-stage renal disease. This is an update of a review first published in 2017.
## OBJECTIVES
To assess the...
ls registers.
## SELECTION CRITERIA
Randomised controlled trials (RCTs) comparing interventions to prevent or reduce kidney complications or CKD in people with SCD. We applied no restrictions related to outcomes examined, language, or publication status.
## DATA COLLECTION AND ANALYSIS
Two revie...
ed nine to 18 months. We are unsure if hydroxyurea compared to placebo reduces or prevents progression of kidney disease assessed by change in glomerular filtration rate (mean difference (MD) 0.58 mL/min /1.73 m2, 95% confidence interval (CI) -14.60 to 15.76; 142 participants; very low certainty). H...
Fragen zu diesem Thema?
ClariMed durchsucht alle Leitlinien mit KI und liefert quellenbasierte Antworten in Sekunden.
Jetzt auf ClariMed suchenVerwandte Leitlinien
StatPearls2026
StatPearls: Sickle Cell Nephropathy
Cochrane2020
Cochrane Review: Interventions for preventing silent cerebral infarcts in people with sickle cell disease
Cochrane2022
Cochrane Review: Hydroxyurea (hydroxycarbamide) for sickle cell disease
Cochrane2023
Cochrane Review: Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease
Cochrane2024